Navigation Links
XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512,in Restless Legs Syndrome

>Additional XP13512 Phase 3 Clinical Trials in RLS

XenoPort is conducting two additional Phase 3 clinical trials, including a second 12-week, double-blind, placebo-controlled Phase 3 clinical trial with the same co-primary and similar secondary endpoints as the trial for which results were announced today. In addition to 1200 mg of XP13512, this trial is also evaluating 600 mg of XP13512. The trial is expected to enroll approximately 300 RLS patients.

XenoPort is also conducting a Phase 3 clinical trial assessing the long-term efficacy of XP13512 using a placebo-controlled, "randomized withdrawal" design to evaluate relapse of RLS symptoms in XP13512-treated or placebo-treated patients who had previously achieved clinical improvement while taking 1200 mg of XP13512 for 24 weeks.

About XP13512 Collaborations

In December 2005, XenoPort licensed to Astellas Pharma Inc. rights to develop and commercialize XP13512 in Japan, Korea, the Philippines, Indonesia, Thailand and Taiwan. In February 2007, XenoPort entered into a collaboration with GlaxoSmithKline (GSK) for the development and commercialization of XP13512 in all countries of the world, excluding the Astellas territory.

XenoPort has received up-front and milestone payments totaling $110 million from these collaborations. It is eligible to receive additional potential milestone payments of up to $615 million, including a $5 million milestone payment from Astellas for the completion of the Phase 3 clinical trial for which results were announced today.

Results of XP13512 in Restless Legs Syndrome

XenoPort is entitled to receive royalties on any product sales under both collaborations and has an option to share profits and co-promote XP13512 with GSK in the United States. The GSK agreement provides that XenoPort will complete its Phase 3 clinical development program of XP13512 for the treatment of RLS and that GSK will file the NDA in the U.S. for this indication. GSK is
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:12/14/2009)... Fla., Dec. 14 Perry Baromedical, international ... announces the launch of the Sigma Elite, with ... of the Sigma Elite is available on each ... and has a Patent Pending. ,, The Sigma ... Data Capture Via Computerized System for Each Dive ...
(Date:12/14/2009)... DENVER, Dec. 14 Corgenix Medical ... developer and marketer of diagnostic test kits, ... Massachusetts-based life sciences company, announced today a ... Galectin-3 diagnostic products in enzyme-linked immunosorbent assay ... BG Medicine is seeking regulatory clearance in ...
(Date:12/14/2009)... Inc. is pleased to announce that the United ... number 7,599,057 titled "Method and Apparatus for Detection ... company. The patent covers the core technology which ... of this patent supports the underlying strategy as ... commercialization," said Dave Dingott, CEO and President of ...
Breaking Medicine Technology:Perry Baromedical Announces New Cutting Edge Technology With Patient Data Capture Capability 2Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM) 2Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 1Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 2Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 3Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 4Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 1Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 2Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 3Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 4Fifteenth US Patent Issued for aTyr Pharma Novel Biotherapeutic 56522 1Fifteenth US Patent Issued for aTyr Pharma Novel Biotherapeutic 56522 2
... therapeutic cancer vaccine,trials have yet to show evidence ... tumors -- yet patients who,receive these vaccines in ... subsequent treatment. In the July 1 issue of ... for Cancer,Research, a team of National Cancer Institute ...
... India, July 5th, 2007 – Several data,presentations ... be presented at ,International Brain Research ... be held at Melbourne, Australia during,July 12-17, ... will be presenting new,data for 4 promising ...
Other Medicine Technology:From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 2From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 3Suven Life Sciences Presenting Pre-clinical data of their,NCE’s SUVN-502 and SUVN-507at International Brain Research,Organization (IBRO) 2007 World Congress of Neuroscience 2
(Date:12/15/2009)... understand how to make an AIDS vaccine have found ... that the immune system can indeed produce cells with ... at the same time, the immune system works equally ... they have a chance to mature. , "These studies ... viral disease is under the control of immunological tolerance," ...
(Date:12/15/2009)... about-face, the secretive Central Intelligence Agency has requested documents from ... them from the CIA itself under the Freedom of Information ... ... 15, 2009 -- In a bizarre about-face, the secretive Central ... though the writer had earlier obtained them from the CIA ...
(Date:12/15/2009)... Landing on granite sand is deemed safer than wood fiber ... a child will break an arm in a fall are ... those with wood fiber surfaces, new research has found. , ... at 19 schools that had playground surfaces of either granite ... Dec. 14 in PLoS Medicine . , The risk ...
(Date:12/15/2009)... Seattle’s premier organic meal delivery service ( www.delicious-planet.com ) is ... Detox Program, Randi Carter, company founder and CEO reported today. ... ... – Seattle, WA) – Delicious Planet, Seattle’s premier organic meal ... the launch of its Delicious Planet Detox Program, Randi Carter, ...
(Date:12/15/2009)... -- At a time when Americans spend over $50 ... Dr. Raymond Hall is theorizing a painful connection between ... solution called Pillo1 ( www.pillo1.com ) to address the ... St. John,s Medical Plaza Sleep Disorders Center showed that ... sleeping position and promotes increased time spent in REM ...
Breaking Medicine News(10 mins):Health News:Biological catch-22 prevents induction of antibodies that block HIV 2Health News:CIA Requests its Own Documents from Author 2Health News:CIA Requests its Own Documents from Author 3Health News:Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery 2Health News:Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery 3Health News:Delicious Planet Organic Meal Service Is Accepting Orders For Its Weekly Detox Program Delivery 4Health News:Sleep Study Shows Pillo1 Re-Educates Body to Naturally Move Into Optimal Sleep Position and Increases REM Sleep by 21.3% 2
... learn by looking at the spines of hundreds of Finnish ... the Twin Spine Study, you find compelling proof that back ... physical strain. , The findings of the Twin Spine Study, ... a dramatic paradigm shift in the way disc degeneration is ...
... people living with chronic diseases, such as multiple sclerosis ... they must manage symptoms and treatments that cause increased ... researchers from two universities have found that people with ... depression and improve the overall quality of their lives. ...
... adolescence, study found , , TUESDAY, April 8 (HealthDay News) -- ... finds, but the impact of these factors change with age. ... from 1985 to 1986. The twins were assessed for levels ... to 14, ages 16 to 17 and ages 19 to ...
... whether it makes difference in high-risk groups, study finds ... study that weighed whether aggressively lowering cholesterol levels and ... disease is worth the effort did not produce a ... involved 499 American Indians with diabetes, found the strategy ...
... numbers tell the,story, Vicki Hoak, executive director of the ... Youth Committee today.,The Medicaid reimbursement for a year of ... an acute care hospital, the bill could be several ... Since the Governor and legislators agree that homecare is ...
... WASHINGTON, April 8, 2008 The following is a,statement of ... and is central to the health and,vitality of any democratic ... leaders have engaged in,an open and full debate over the ... SEIU,s strategies and ideas have been the subject of,an even ...
Other Medicine News:Health News:Award-winning study says back pain may be in your genes 2Health News:Increasing positive experiences decreases depression symptoms in patients with multiple sclerosis 2Health News:Genes' Influence on Fears Changes Over Time 2Health News:Aggressive Cholesterol, Blood Pressure Treatment Shows Some Benefit 2Health News:Aggressive Cholesterol, Blood Pressure Treatment Shows Some Benefit 3Health News:Since Governor and Legislators Agree on Value of Homecare, Advocacy Group Says Time is Now to Make it Available to More Pennsylvanians 2Health News:Since Governor and Legislators Agree on Value of Homecare, Advocacy Group Says Time is Now to Make it Available to More Pennsylvanians 3
Auto Plate Washer: 96-well washing. The ELx405 Auto Washer is the most precise and reliable washer available. Many unique features lower background absorbance values and increase the signal-to-noise ...
The Benchmark Microplate Reader, with its increased wavelength range of 340 to 750 nm and high performance optics, provides flexibility for specialized applications requiring increased linearity, ult...
Elisa strip reader...
Iems Incubator/Shaker expansion module for 2 module incubator/shaker. high performance microplate incubator and orbital shaker. It's superior temperature control and efficient orbital shaking reduce ...
Medicine Products: